Previous studies have shown that CDX2 expression is limited not only to normal intestinal cells, but also is expressed in gastric carcinoma, colorectal cancer, thyroid cancer, ovarian cancer, urinary bladder carcinoma and prostate adenocarcinoma [15–19]. This evidence concerns the gene CDX2 and ovarian carcinoma.